2016년 3월 31일 바이오 코리아에서 발표한 그 당시 최근의 제약바이오의 변화와 미래 추정...

1. Recent Trends and Changes
in R&D /BD among Korean
biopharmas
James Jungkue Lee
Bridge Biotherapeutics, Inc
BioKorea 2016
1

2. Opening
• Korea biopharma industry has undergone profound changes in 2015/6
season, 30 years after Korea government amended patent law to
implement COM (composition of matter) patent in 1987. Hanmi’s strings
of super deals in 2015 has raised the level of self-confidence across
Korea biopharma industry and has made ex-Korea biopharma industry
players consider Korea emerging and proven source of innovations. In
such internal and external changes, pharmas and biotechs has
cautiously introduced changes into its R&D and BD strategy. This
presentation will try to recap such changes in last 12 months and
suggest several recommendations to Korean and ex-Korean biopharma.
2

3. Bridge Biotherapeutics, Inc.
• Virtually operating biotech
• A novel target biology with potential for multiple
indications
• IND-enabling GLP study will be initiated in H2, 2016
3

4. Korean Biopharma industry -
Genesis
ü1988
• Adoption of ”COM” patent
• NCE discovery (mostly me-too approach) started
ü1997
• First wave of licensing-out to big pharma
• LG Life Sciences, Yuhan, SK Corp
4

5. Korean Biopharma industry -
Genesis
5

6. Korean Biopharma industry -
Genesis
6

7. Korean Biopharma industry -
Growth
ü1999/2000
• > 200 biotech startups
• Traditional pharmas started NCE/NME research
ü2015
• Hanmi Pharma’s serial home-run deals
7

8. Korean Biopharma industry -
Growth
8

9. Korean Biopharma industry - Now
üVC industry is getting smarter.
• More experienced venture capitals
• Fund size has increased
üAcademia continues to bring novel sciences
• Mature science
• Professor/academic researchers started to respect
industry
üIndustry
• Hunger for novelty due to continued failure with “me-
too” approach
9

10. Korean Biopharma industry - Now
and Near Future
10

11. Current Trends
üBiotech sector is getting mature.
• More clinical stage assets being developed globally
• Seasoned entrepreneur and BD executives
• Experienced venture capitals
üNovel sciences spring out from academia
• New wave of startups from academia or established
companies
üBiotechs are getting virtualized
• Ecosystem is getting mature to support virtual biotechs.
11

12. Current Trends - Virtualization
• Skilled Management
• Seasoned venture
capital
• Vendor network
(regional and global)
• Cutting-edge science
12

13. Current Trends – Novel science
• Hanmi- the last success
of “me-too or me-
better” approach?
• Novel targets
• Strong and proprietary
biology
13

14. Current Trends – BD expertise
• Experienced BD
executive, home-grown
and expats
• More options and
flexibilities in deal
structures
14

15. Bridge Biotherapeutics
• Internal team: 3+
• Target Biology : Pellino-1, validated by SKKU
• Asset: BBT-401(PPI), optimized by KRICT
• Indication: IBD +
• Collaboration network
• Universities – Korean and UK
• CRO – Korean, China and US
• Collaboration network
• Clinical development : US IND filing aimed at 2H,
2017
15

16. Qurient Therapeutics
• A spin-off from Institut Pasteur Korea
• Semi-virtual operation with strong PM capability
• One P2 asset in USA for atopic dermatitis, discovered
by drug repurposing
• One P1 asset in USA, orphan drug designated by US
FDA for the treatment of TB.
• KOSDAQ IPO this year
16

17. Oscotec/Genosco
• Genosco (Boston, US) is a spin-off from Oscotec.
KOSDAQ-traded Korean corporation.
• Established as US corporation in Boston
• Semi-virtual operation
• Two assets (SYKi and FLT3i) are at P1 in USA
17

18. ImmunoMet Therapeutics Inc
• A spin-off from Hanall BioPharma with IND-ready
asset in cancer metabolism space.
• US corporation, headquartered in Boston.
• Laboratories located at JLAB, Houston, Texas.
• Series A of $5m completed recently.
18

19. Biotech A
• A spin-off from a prestigious university.
• University TLO has minor but meaningful equity
position.
• Novel biology (GPCR and CNS) with potential
indications for high-unmet needs CNS diseases
• Scientific founder vs. management team
19

20. Yuhan Corp.
• Very active in open innovation to overcome
relatively weak internal capability
• ImmuneOncia Therapeutics, LLC , Joint venture
with Sorrent Therapeutics, US-based biotech
• Regional right for the first asset and global right for
the following assets
20

21. Implications to BD
• Active pre-marketing at various international partnering
events (JP Morgan, BIO, BioEurope etc)
• Increasing number of big pharma companies seeking Korean
innovations very actively and a couple of them try to get
local.
• Korean pharma companies (eg., Hanmi, DongA, Yuhan,
BuKwang and etc.) are setting up CVC function internally or
externally.
21

22. Korean biopharma industry, active
participants in global biophama
industry as innovation sources
22

23. 23
James Junkue Lee
CEO, Bridge Biotherapeutics, Inc.
James.Lee@Bridgebiorx.com